Repair Bio: Cholesterol Inside the Wall
Repair Biotechnologies targets cholesterol trapped inside arterial plaque cells via LNP-delivered mRNA — preclinical, with 48% plaque lipid reversal reported in mice and no human data after 8 years on $2.15M seed funding.
Repair Biotechnologies, founded 2018, Syracuse, NY. One platform, one idea: destroy the cholesterol already trapped inside arterial wall cells — not the cholesterol circulating in your blood.
The company's core claim: localized accumulations of excess cholesterol inside cells drive atherosclerotic plaque. Their Cholesterol Degrading Platform delivers mRNA via lipid nanoparticles to degrade cholesterol directly inside affected cells. The lead candidate is REP-0003.
Repair Bio reported 48% reversal of atherosclerotic plaque lipids in a mouse model. The company also presented preclinical data at the American Heart Association's Scientific Sessions in 2025 showing plaque regression with REP-0003 treatment. Mice, not humans — but plaque regression was measured.
Regulatory progress centers on homozygous familial hypercholesterolemia (HoFH), a rare disease with severely impaired inherited lipid handling and extreme cholesterol burden. The FDA granted the program RDEP eligibility (Rare Disease Endpoint Advancement Program). The company says it plans to file an IND application.
What is missing: independent replication, peer-reviewed publications on the platform itself, any human clinical data. The named programs — atherosclerosis, HoFH, steatohepatitis — are preclinical. A fourth liver indication appears in the pipeline with no disclosed development stage. One platform, several indication variants.
The company is eight years old on a $2.15M seed round. Checkable public claims held up; we found no contradictions — but claims without published data on the lead candidate are still just claims.
The hypothesis is falsifiable and specific: if intracellular cholesterol degradation works, plaque burden should decrease. If it doesn't, the theory is wrong.
The intracellular cholesterol degradation mechanism is genuinely distinct from standard lipid-lowering and rarely attempted, making it worth explaining — while the 8-year preclinical timeline on minimal capital and absent independent replication provide an honest counterweight that matches the Eternal Search voice.